Here is the design of a clinical trial:

Official Title: Efficacy of Ballet Dancing on Motor and Non-motor Symptoms of Parkinson's Disease: a Hybrid Type 2 Effectiveness-implementation Trial

Included conditions:
- Parkinson Disease

Study Armgroups:
- {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'interventionNames': ['Other: Dance with ballet elements']}
- {'label': 'Usual Treatment', 'type': 'NO_INTERVENTION', 'description': "usual treatment with the addition of joining 'Tea and Biscuit' sessions remotely"}

Interventions:
- {'type': 'OTHER', 'name': 'Dance with ballet elements', 'description': 'Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.', 'armGroupLabels': ['Intervention']}

Primary Outcomes:
- {'measure': 'Change in total score of the Movement Disorders Society Sponsored Non-Motor Rating Scale', 'description': 'Clinical Effectiveness Primary Outcome Measure, higher score indicate worse non-motor symptomatology, the maximum score is 1008.', 'timeFrame': 'Baseline (week -4 to 0), end of intervention (week 12-14) and up to 24 weeks post intervention depending on participant availability'}
- {'measure': 'Acceptability of Intervention Measure', 'description': 'Implementation Effectiveness Primary Outcome Measure - a 4 item, 5-point likert scale', 'timeFrame': 'post intervention (week 12)'}

Please estimate the sample size based on the assumption: 
80% power, 5% significance level, 10% attrition rate, superiority study at immediate follow-up
Sample size
        Given that no previous studies explored the effect of ballet dancing on the symptoms of PD, sample size calculation is based on detecting a significant difference between intervention and the control group in the mean changes from baseline to follow-up in the primary outcome (MDS-NMS). To date, no clinical trials have yet utilised MDS-NMS as an outcome measure due to its novelty. As such, our estimation of the sample size is based on detecting a medium effect size (Cohenâs d 0.5) with 80% power and 5% significance, resulting in the total of 144 participants. Given that the randomisation ratio is 2:1, the intervention group is expected to include 96 participants and the control group 48 participants. Allowing a 10% attrition rate for the final analysis, the total number of participants in the study will be 160. The study is powered as a superiority study at immediate follow-up.